About Contact Us Careers

Anti-Venom Market - Top Companies and Manufacturers

Request Free Sample Copy

Report ID: 3755
Published Date: Aug 23, 2024
Report Format: PDF, PPT

Buy Now

Companies Dominating the Anti-Venom Landscape

Bharat Serums and Vaccines, Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Haffkine Bio-Pharmaceutical Corporation Limited
Boston Scientific Corporation
CSL Limited
Flynn Pharma Ltd (Micropharm)
Medtoxin Venom Laboratories LLC
Merck & Co. Inc.
Pfizer Inc.
Rare Disease Therapeutics Inc.
Amgen Inc.

Browse Key Market Insights with Data Illustration:

Anti-Venom Market Size & Share, Growth Trends 2036

In the News

April, 2021: Rare Disease Therapeutics, Inc. announced the approval from United States (US) Food & Drug Administration (FDA) of a new expanded indication for ANAVIP, an equine-derived antivenin.

Author Credits: Radhika Pawar

Report ID: 3755
Published Date: Aug 23, 2024
Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of anti-venom is evaluated at USD 721.77 million.

Anti-Venom Market size was valued at USD 674.8 million in 2023 and is set to cross USD 1.99 billion by 2036, expanding at more than 8.7% CAGR during the forecast period i.e., between 2024-2036. Technological innovation in the treatment for envenoming, and rising awareness about available anti-venoms, will boost the market growth.

Asia Pacific industry is estimated to account for largest revenue share by 2036, led by growing cases of snakebites, which require anti-venom for treatment.

The major players in the market are CSL Limited, Flynn Pharma Ltd (Micropharm), Medtoxin Venom Laboratories, Merck & Co. Inc., Pfizer Inc., Rare Disease Therapeutics Inc., Amgen Inc., and others.

Inquiry Before Buying Request Free Sample